BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29083975)

  • 1. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 3. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.
    Choong CK; Ford JH; Nyhuis AW; Robinson RL; Aurora SK
    J Manag Care Spec Pharm; 2018 Sep; 24(9):921-928. PubMed ID: 30156448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
    Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
    J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
    [No Abstract]   [Full Text] [Related]  

  • 12. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
    Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.
    Guo A; Niyazov A; Macaulay D; Terasawa E; Schmerold L; Wu EQ; Krieger S
    J Manag Care Spec Pharm; 2017 Jul; 23(7):771-780. PubMed ID: 28650249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
    Lipton RB; Lee L; Saikali NP; Bell J; Cohen JM
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
    Bibeau WS; Fu H; Taylor AD; Kwan AY
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.